scholarly journals The relationship between p53, Bcl2 proteins and histological grade in colorectal adenocarcinoma associated with type 2 diabetes and obesity

2020 ◽  
Vol 79 (OCE2) ◽  
Author(s):  
Popescu-Vâlceanu Horaţiu-Cristian ◽  
Stoicea Mihai ◽  
Enache Valentin ◽  
Mustatea Petronel ◽  
Rusu Emilia ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Adenocarcinoma ◽  
Histological Grade ◽  
P53 Protein ◽  
Diabetic Patients ◽  
Reference Laboratory ◽  
Low Grade ◽  
Colorectal Tumors ◽  
Type 2 Diabetic

AbstractIntroductionThe aim of our study was to evaluate the expression of p53 protein in colorectal adenocarcinoma in diabetic (type 2) obese vs non-obese vs and to analyse p53, Bcl2 proteins expression in type 2 diabetic vs non-diabetic patients based on histological grade.Material and MethodsIn a retrospective study we analyzed all hospitalized patients with colorectal cancer between 2011–2015 in Bucharest Emergency Hospital, according to International Statistical Classification of Diseases classification and Related Health Problems 10th Revision.The p53 and Bcl2 proteins expressions were investigated by automated immunohistochemistry BenchMark XT Ventana platform using dual Bcl2-p53 protocol in the Histopathology Department of the Central Reference Laboratory Synevo.ResultsWe identified in order of appearance only the cases with appropriate inclusion criteria, 95 cases of colorectal adenocarcinoma: 52 were type 2 diabetic patients (33males /19 females, mean age 70.2 years) and 43 non-diabetics (30 males /13 females mean age 69.5 years). There were 15vs2 obese subjects in diabetic/non-diabetic patients compared to 37vs41 with normal weight.Our data showed that obese diabetic patients associate more frequently the overexpression of p53 protein in colorectal adenocarcinoma in the 80% (12/15 of cases) comparative with non-obese diabetic patients 40.5% (15/37 cases) or non-diabetics and non-obese controls 36.6% (15/41 cases p = 0.024).Regarding histological grade, diabetic patients associated low-grade colorectal tumors (78.8% of cases) compared with non-diabetics (58.1% of cases) and non-diabetic patients associated high-grade colorectal tumors increased (41.9%) compared to diabetics (21.2%), with statistical significance (p = 0.043).Diabetics compared with non-diabetics associated an oversexpression of all immunophenotypes in the low histological grade colorectal adenocarcinoma: Bcl2-/p53- immunophenotype in 62% vs 53% of cases (p = 0.836); for Bcl2 + / p53- immunophenotype in 67% vs 43% of cases (p = 0.064); for Bcl2-/p53 + immunophenotype in 77% vs 71% of cases (p = 0.489) and for Bcl2 + /p53 + immunophenotype in 100% vs33% of cases (p = 0.333).DiscussionIt is known that the protein p53 is a powerful transcriptor factor acting as checkpoint controlling the differentiation of the various cells including adipocytes and also possible enterocytes (explaining the higher frequency of colorectal cancer which has been associated with the increased proliferation of adipocytes characterizing the obesity).Due to the protection conferred by a normal p53 protein its upregulation could be a new target for the treatment of obesity. Interesting our work revealed that diabetic patients associated low-grade colorectal adenocarcinoma with an oversexpression of all immunophenotypes.

scholarly journals Serum IL-17, IL-23, and TGF-βLevels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Azam Roohi ◽  
Mina Tabrizi ◽  
Farzaneh Abbasi ◽  
Asal Ataie-Jafari ◽  
Behrouz Nikbin ◽  
...  
Keyword(s):  
Serum Levels ◽  
Diabetic Patients ◽  
Low Grade ◽  
Healthy Controls ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Type 1 Diabetic Patients ◽  
Type 2 Diabetic

Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factorβ(TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-βlevels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-βwere measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-βwas significantly lower in type 1 diabetic patients (P<0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-βlevels were lower in type 1 diabetic patients.

scholarly journals Risk of Colorectal Cancer in Type 2 Diabetic Patients: A Population-based Cohort Study

2013 ◽  
Vol 43 (3) ◽  
pp. 258-263 ◽  
Author(s):  
Jen-Yu Wang ◽  
Ting-Ting Chao ◽  
Chih-Cheng Lai ◽  
Cheng-Yi Wang ◽  
Vin-Cent Wu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Correlation between Expression Profiles of Key Signaling Genes in Colorectal Cancer Samples from Type 2 Diabetic and Non-Diabetic Patients

Life ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 216
Author(s):  
Zsuzsanna Elek ◽  
Zsolt Rónai ◽  
Gergely Keszler ◽  
László Harsányi ◽  
Endre Kontsek ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Internal Control ◽  
Expression Profiles ◽  
Expression Patterns ◽  
Enrichment Analysis ◽  
Differentially Expressed ◽  
Diabetic Patients ◽  
Mrna Levels ◽  
Type 2 Diabetic

Several lines of epidemiological and biochemical evidence support the association of type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC). T2DM has been shown to impinge on the transcriptome of colon tumor cells, promoting their proliferation and invasion. In order to gain insight into diabetes-specific modulation of colon cancer signaling, we analyzed gene expression patterns of more than five hundred genes encoding signaling proteins on TaqMan OpenArray panels from colonoscopic colorectal tumor samples of type 2 diabetic and non-diabetic patients. In total, 48 transcripts were found to be differentially expressed in tumors of T2DM patients as compared to healthy colon samples. Enrichment analysis with the g:GOSt (Gene Ontology Statistics) functional profiling tool revealed that the underlying genes can be classified into five signaling pathways (in decreasing order of significance: Wnt (wingless-type)/β-catenin; Hippo; TNF (tumor necrosis factor); PI3K/Akt (phosphoinositide-3 kinase/protein kinase B), and platelet activation), implying that targeted downregulation of these signaling cascades might help combat CRC in diabetic patients. Transcript levels of some of the differentially expressed genes were also measured from surgically removed diabetic and non-diabetic CRC specimens by individual qPCR (quantitative real-time PCR) assays using the adjacent normal tissue mRNA levels as an internal control. The most significantly altered genes in diabetic tumor samples were largely different from those in non-diabetic ones, implying that T2DM profoundly alters the expression of signaling genes and presumably the biological characteristics of CRC.

Sign in / Sign up

Export Citation Format

Share Document